Skip to main content
Terug
HLN logo

Haleon plc

Datakwaliteit: 100%
HLN
NYSE Healthcare Drug Manufacturers - Specialty & Generic
€ 9,70
▼ € 0,23 (-2,32%)
Marktkapitalisatie: 43,19B
Ook genoteerd als HLNCF OTC
Dagbereik
€ 9,65 € 9,77
52-Weeksbereik
€ 8,71 € 11,42
Volume
14.484.580
50D / 200D Gem.
€ 10,51 / € 9,91
Vorige Slotkoers
€ 9,93

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 26,5 0,3
P/B 2,6 2,9
ROE % 10,0 3,7
Net Margin % 15,1 3,8
Rev Growth 5Y % 3,1 10,0
D/E 0,5 0,2

Koersdoel Analisten

Hold
€ 10,20 +5.2%
Forward K/W
24,1
Forward WPA
€ 0,41
WPA Groei (sch.)
+0,0%
Omzet Sch.
11 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,56
€ 0,55 – € 0,57
13 B 2
FY2029 € 0,55
€ 0,54 – € 0,56
13 B 4
FY2028 € 0,50
€ 0,45 – € 0,54
12 B 6

Belangrijkste Punten

Revenue grew 3,11% annually over 5 years — modest growth
ROE of 10,01% — decent returns on equity
Net margin of 15,11% shows strong profitability
Generating 1,97B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,07%
Cash machine — converts 120,88% of earnings into free cash flow

Groei

Revenue Growth (5Y)
3,11%
Revenue (1Y)-3,96%
Earnings (1Y)13,07%
FCF Growth (3Y)5,70%

Kwaliteit

Return on Equity
10,01%
ROIC7,27%
Net Margin15,11%
Op. Margin22,44%

Veiligheid

Debt / Equity
0,52
Current Ratio0,92
Interest Coverage7,28

Waardering

P/E Ratio
26,49
P/B Ratio2,63
EV/EBITDA20,85
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3,96% Revenue Growth (3Y) -2,30%
Earnings Growth (1Y) 13,07% Earnings Growth (3Y) 24,67%
Revenue Growth (5Y) 3,11% Earnings Growth (5Y) 4,07%
Profitability
Revenue (TTM) 10,79B Net Income (TTM) 1,63B
ROE 10,01% ROA 5,01%
Gross Margin 64,77% Operating Margin 22,44%
Net Margin 15,11% Free Cash Flow (TTM) 1,97B
ROIC 7,27% FCF Growth (3Y) 5,70%
Safety
Debt / Equity 0,52 Current Ratio 0,92
Interest Coverage 7,28 Dividend Yield 0,02%
Valuation
P/E Ratio 26,49 P/B Ratio 2,63
P/S Ratio 4,00 PEG Ratio 1,65
EV/EBITDA 20,85 Dividend Yield 0,02%
Market Cap 43,19B Enterprise Value 50,46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10,79B 11,23B 11,30B 10,86B 9,55B
Net Income 1,63B 1,44B 1,05B 1,06B 1,39B
EPS (Diluted) 0,36 0,32 0,24 0,24 0,30
Gross Profit 6,99B 6,95B 6,96B 6,58B 5,95B
Operating Income 2,42B 2,21B 2,00B 1,83B 1,64B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 32,57B 34,32B 34,06B 34,82B 34,45B
Total Liabilities 16,12B 18,09B 17,33B 18,36B 7,97B
Shareholders' Equity 16,40B 16,17B 16,61B 16,33B 26,36B
Total Debt 8,59B 10,10B 9,46B 10,44B 991,00M
Cash & Equivalents 1,32B 2,20B 1,04B 684,00M 414,00M
Current Assets 4,54B 5,72B 4,82B 4,06B 5,25B
Current Liabilities 4,92B 5,81B 4,64B 4,37B 4,24B